Proactive Investors - Run By Investors For Investors

G Medical Innovations signs key agreements with US health service providers

The company continues to increase its market share and operations across the US in the lead up towards its proposed NASDAQ dual listing.
doctor and patient
New agreements are an opportunity to increase revenue

G Medical Innovations Holdings Ltd (ASX:GMV) has executed key provider participation agreements with Prime Health Services Inc (PHS) and Ancillary Care Services (ACS) in the US territory.

The agreement was made by G Medical’s wholly-owned subsidiary G Medical Diagnostic Services Inc (GMEDx).

GMEDx owns two Independent Diagnostic Testing Facility (IDTF) and Mobile Cardiac Telemetry (MCT) operations being, ‘Telerhythmics’ and ‘Cardiostaff’.

READ: G Medical Innovations acquires Telerhythmics, expands US footprint

The two operations have been successfully integrated with the synergies realising month on month growth in patient numbers.

With the addition of the new provider participation agreements (PPA), GMEDx has further increased its footprint in the healthcare delivery system of cardiac monitoring to provide more exposure to its future patient base and third-party payer populations.

READ: G Medical Innovations secures first US commercial orders valued at almost US$22 million

Obtaining additional access to Medicare reimbursements for services rendered to covered persons under the PPA with PHS and ACS will translate to increased revenue opportunity for GMEDx, as these services are carried out based on individual patient requirements, the treatment modalities utilised and term and frequency of treatment.

There is no immediate revenue impact from the PPAs, and the future revenue opportunity to GMEDx is subject to PHS’s and ACS’s individual patient requirements.

READ: G Medical Innovations advances mobile health technologies in March quarter

G Medical CEO Dr Yacov Geva said: “I am pleased to update our shareholders on the continued expansion of our footprint and relationships in the key US market.

“Our new partners are both long-standing and well-respected multi-faceted health service providers of the highest quality in this territory.

“Through this, we importantly continue to increase our market share and operations across the US in the lead up towards our proposed NASDAQ dual listing.”

View full GMV profile View Profile

G Medical Innovations Holdings Ltd Timeline

Related Articles

The company expects to open its vault for even more cash takings
January 22 2019
Contracted revenues were $3.7 million last quarter but didn’t include Solo app sales for Samsung watches.
The "St. Noire" video game
March 24 2019
The company embraces digital interactive entertainment as well as augmented reality, virtual reality and artificial intelligence
lung
June 11 2019
Company has developed a drug-device combination, which uses hyperpolarised 129-Xenon gas MRI.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use